全文获取类型
收费全文 | 15692篇 |
免费 | 694篇 |
国内免费 | 71篇 |
专业分类
耳鼻咽喉 | 270篇 |
儿科学 | 301篇 |
妇产科学 | 234篇 |
基础医学 | 2117篇 |
口腔科学 | 389篇 |
临床医学 | 967篇 |
内科学 | 3686篇 |
皮肤病学 | 338篇 |
神经病学 | 1285篇 |
特种医学 | 743篇 |
外科学 | 2671篇 |
综合类 | 84篇 |
一般理论 | 1篇 |
预防医学 | 521篇 |
眼科学 | 358篇 |
药学 | 848篇 |
中国医学 | 32篇 |
肿瘤学 | 1612篇 |
出版年
2023年 | 63篇 |
2021年 | 219篇 |
2020年 | 153篇 |
2019年 | 195篇 |
2018年 | 256篇 |
2017年 | 215篇 |
2016年 | 285篇 |
2015年 | 298篇 |
2014年 | 341篇 |
2013年 | 481篇 |
2012年 | 776篇 |
2011年 | 885篇 |
2010年 | 481篇 |
2009年 | 383篇 |
2008年 | 746篇 |
2007年 | 767篇 |
2006年 | 873篇 |
2005年 | 863篇 |
2004年 | 867篇 |
2003年 | 859篇 |
2002年 | 837篇 |
2001年 | 448篇 |
2000年 | 493篇 |
1999年 | 460篇 |
1998年 | 227篇 |
1997年 | 196篇 |
1996年 | 154篇 |
1995年 | 179篇 |
1994年 | 126篇 |
1993年 | 110篇 |
1992年 | 247篇 |
1991年 | 273篇 |
1990年 | 262篇 |
1989年 | 268篇 |
1988年 | 264篇 |
1987年 | 252篇 |
1986年 | 211篇 |
1985年 | 184篇 |
1984年 | 151篇 |
1983年 | 112篇 |
1982年 | 67篇 |
1981年 | 71篇 |
1980年 | 56篇 |
1979年 | 102篇 |
1978年 | 54篇 |
1976年 | 54篇 |
1972年 | 67篇 |
1971年 | 52篇 |
1970年 | 48篇 |
1969年 | 59篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Harada Hideyuki Omori Shota Mori Keita Konno Masahiro Murakami Haruyasu Imagumbai Toshiyuki Fukuda Haruyuki Nakamatsu Kiyoshi Kimura Tomoki Tanabe Hiroaki Fujita Hideki Tatebe Hitoshi Fujitaka Kazunori Nishimura Yasumasa 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(6):1025-1033
International Journal of Clinical Oncology - This multi-institutional clinical trial evaluated the feasibility of intensity-modulated radiotherapy (IMRT) for patients with locally advanced... 相似文献
2.
Takehiko Mori Souichi Shiratori Junji Suzumiya Mineo Kurokawa Motohiro Shindo Uchida Naoyuki Takenaka Katsuto Toshihiro Miyamoto Satoshi Morishige Makoto Hirokawa Takahiro Fukuda Yoshiko Atsuta Ritsuro Suzuki 《Hematological oncology》2020,38(3):266-271
Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome. 相似文献
3.
T. Sunohara H. Imamura M. Goto R. Fukumitsu S. Matsumoto N. Fukui Y. Oomura T. Akiyama T. Fukuda K. Go S. Kajiura M. Shigeyasu K. Asakura R. Horii C. Sakai N. Sakai 《AJNR. American journal of neuroradiology》2021,42(1):119
BACKGROUND AND PURPOSE:With the increasing use of the Pipeline Embolization Device for the treatment of aneurysms, predictors of clinical and angiographic outcomes are needed. This study aimed to identify predictors of incomplete occlusion at last angiographic follow-up.MATERIALS AND METHODS:In our retrospective, single-center cohort study, 105 ICA aneurysms in 89 subjects were treated with Pipeline Embolization Devices. Patients were followed per standardized protocol. Clinical and angiographic outcomes were analyzed. We introduced a new morphologic classification based on the included angle of the parent artery against the neck location: outer convexity type (included angle, <160°), inner convexity type (included angle, >200°), and lateral wall type (160° ≤ included angle ≤200°). This classification reflects the metal coverage rate and flow dynamics.RESULTS:Imaging data were acquired in 95.3% of aneurysms persistent at 6 months. Complete occlusion was achieved in 70.5%, and incomplete occlusion, in 29.5% at last follow-up. Multivariable regression analysis revealed that 60 years of age or older (OR, 5.70; P = .001), aneurysms with the branching artery from the dome (OR, 10.56; P = .002), fusiform aneurysms (OR, 10.2; P = .009), and outer convexity–type saccular aneurysms (versus inner convexity type: OR, 30.3; P < .001; versus lateral wall type: OR, 9.71; P = .001) were independently associated with a higher rate of incomplete occlusion at the last follow-up. No permanent neurologic deficits or rupture were observed in the follow-up period.CONCLUSIONS:The aneurysm neck located on the outer convexity is a new, incomplete occlusion predictor, joining older age, fusiform aneurysms, and aneurysms with the branching artery from the dome. No permanent neurologic deficits or rupture was observed in the follow-up, even with incomplete occlusion.Flow-diversion stents with the Pipeline Embolization Device (PED; Medtronic) were first reported in 2008.1 Since then, multiple trials2-6 and retrospective studies3,7,8 have reported the safety and efficacy of the PED in the treatment of intracranial aneurysms. Long-term follow-up data showed a 95.2% occlusion rate at 5 years after treatment3,8 and no evidence of recanalization of previously occluded aneurysms.3 Angiographic and clinical long-term follow-up data are important because incomplete occlusion leads to retreatment or rerupture in coil embolization.9Several factors such as age, sex, smoking, fusiform-type aneurysms, small aspect ratios, and dome-neck ratios have been reported to be predictors of incomplete or complete occlusion.10-17 However, there is debate about outcomes when using these factors because of limited analysis of the confounding factors. Moreover, the follow-up imaging rate of incomplete occlusion is sometimes insufficient (around 50% at 6 months).1 Additionally, the same morphologic indices used in coil embolization were used in previous PED studies, even though the 2 methods are different in their treatment mechanism for aneurysms. The metal coverage ratio (MCR)18-20 is an important metric of PED treatment.Although the MCR correlates with the occlusion rate,19 it is calculated after treatment and additional work-up is needed to acquire it. Therefore, in this study, we introduced a new classification based on the included angle of the parent artery against the neck location for the aneurysm, which can be measured before the PED treatment and complements the MCR: outer convexity type, inner convexity type, and lateral wall type. In addition, we clarified factors, including our new classification, affecting incomplete occlusion and clinical outcome in PED treatment, on the basis of data with a high follow-up rate. 相似文献
4.
Yasushi Sawayama Hidehiro Itonaga Takuya Fukushima Nobuaki Nakano Hiroshi Fujiwara Atae Utsunomiya Takahiro Fukuda Toshihiro Miyamoto Tetsuya Eto Kaname Miyashita Hirohisa Nakamae Masao Ogata Atsushi Yamanoha Yasuhiko Miyazaki Junya Kanda Yoshiko Atsuta Koji Kato ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation 《American journal of hematology》2019,94(5):E143-E146
5.
Hibiki Udagawa Keisuke Kirita Tomoyuki Naito Shogo Nomura Masayuki Ishibashi Reiko Matsuzawa Kakeru Hisakane Yuko Usui Shingo Matsumoto Kiyotaka Yoh Seiji Niho Genichiro Ishii Koichi Goto 《Cancer science》2020,111(7):2488-2498
Cryoprobe is a novel transbronchial biopsy (TBB) tool that yields larger tissue samples than forceps. Pathological diagnosis and biomarker analysis, such as genetic alterations and programmed death‐ligand 1 (PD‐L1) expression, are paramount for precision medicine against lung cancer. We evaluated the safety and usefulness of cryoprobe TBB for lung cancer diagnosis and biomarker analysis. In this single‐center, prospective single‐arm study, patients suspected of having or diagnosed with primary lung cancer underwent cryoprobe TBB using flexible bronchoscopy after conventional forceps TBB from the same lesion. Cryoprobe TBB was performed in 121 patients. The incidence rate of severe bleeding and serious adverse events (4% [90% confidence interval: 2%‐9%]) was significantly lower than the expected rate (20% with 30% threshold, P < 0.01). Combining both central and peripheral lesions, the diagnostic yield rate of cryoprobe samples was 76% and that of forceps samples was 84%. Compared with forceps TBB samples, cryoprobe TBB samples were larger (cryoprobe 15 mm2 vs forceps 2 mm2) and resulted in a larger proportion of definite histomorphological diagnosis (cryoprobe 86% vs forceps 74%, P < 0.01), larger amounts of DNA extracted from samples (median: cryoprobe, 1.60 µg vs forceps, 0.58 µg, P = 0.02) and RNA (median: cryoprobe, 0.62 µg vs forceps, 0.17 µg, P < 0.01) extracted from samples, and tended to yield greater rates of PD‐L1 expression >1% (51% vs 42%). In conclusion, cryoprobe is a safe and useful tool for obtaining lung cancer tissue samples of adequate size and quality, which allow morphological diagnosis and biomarker analysis for precision medicine against lung cancer. 相似文献
6.
7.
Abe Takashi Yabuuchi Akiko Ezoe Kenji Skaletsky Helen Fukuda Junichiro Ueno Satoshi Fan Yuting Goldsmith Sierra Kobayashi Tamotsu Silber Sherman Kato Keiichi 《Journal of assisted reproduction and genetics》2020,37(2):297-304
Journal of Assisted Reproduction and Genetics - To determine age-adjusted overall success rates for patients undergoing clomiphene citrate only minimal stimulation cycle (mini) in vitro... 相似文献
8.
9.
Naoko Shoji Keiji Tanese Ayano Sasaki Taishi Horiuchi Yuji Utsuno Koichi Fukuda Yukiko Hoshino Shinichi Noda Hirofumi Minami Wataru Asakura Amenamevir Review Team 《The Journal of dermatology》2020,47(7):683-688
In July 2017, Japan’s Ministry of Health, Labor and Welfare issued a marketing authorization valid throughout Japan for N-(2,6-dimethylphenyl)-N-(2-{[4-(1,2,4-oxadiazol-3-yl)phenyl]amino}-2-oxoethyl)-1,1-dioxothiane-4-carboxamide (amenamevir) for the first time worldwide. The decision was based on the favorable opinion of the Pharmaceuticals and Medical Device Agency (PMDA) recommending a marketing authorization of amenamevir for treatment of herpes zoster (HZ). Amenamevir has a different action mechanism from previously approved synthetic nucleoside compounds for the treatment of HZ including acyclovir, valacyclovir and famciclovir. The usual adult dose is 400 mg amenamevir p.o. once daily for 7 days. The benefit is its ability to cure HZ as well as preventing postherpetic neuralgia. The most common side-effects are increase of urine N-acetyl-β-D-glucosaminidase and α1-microglobulin levels. However, based on the detailed evaluation of the submitted clinical studies, there seems to be no serious safety concerns about amenamevir regarding the kidney of both renally normal and impaired patients. The objective of this article is to summarize the scientific review of the application. The detailed scientific assessment report and product information, including the summary of product characteristics, are available on the PMDA website ( www.pmda.go.jp/PmdaSearch/iyakuSearch/ ). 相似文献